Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Plus Pucotenlimab in 1L R/M NPC
NCT07381699Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by West China Hospital of Sichuan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07381699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381699.